Company Analysis
Sign in

Psyence Biomedical Ltd. (PBM)

Nasdaq: PBM · Pharmaceutical Preparations · Toronto · filing with the SEC since 2023
Full chart Alerts Compare
Grade5.5
◀ Past 4.4● Present 5.5▶ Future 6.2
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income$1.0M+102.0%
Earnings per share$5.24+100.1%
Operating cash flow-$3.7M-26.8%
Cash$6.1M+736.8%
Debtn/a
Shareholders’ equity$6.7M+161.3%
Shares, diluted193,043+1670.5%
Return on equity15.0%
The recordfrom its filings
Filings in 202632
Newest filingOct 21 · 6-K
Annual reportJun 22, 2026
Quarterly reportn/a
Next report due20-F by Jul 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Oct 5, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PBM · research, not advice